Apyx Medical Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Apyx Medical wird ein Gewinn- und Umsatzwachstum von 19.1% bzw. 11% pro Jahr prognostiziert, während der Gewinn pro Aktie um 30.7% pro Jahr wachsen soll.

Wichtige Informationen

14.1%

Wachstumsrate der Gewinne

47.6%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	17.5%
Wachstumsrate der Einnahmen	11.9%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	13 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Is There An Opportunity With Apyx Medical Corporation's (NASDAQ:APYX) 41% Undervaluation?

Sep 14

Apyx Medical Corporation (NASDAQ:APYX) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Aug 07

We Discuss Why Apyx Medical Corporation's (NASDAQ:APYX) CEO Compensation May Be Closely Reviewed

Aug 01

Is Apyx Medical (NASDAQ:APYX) Using Debt In A Risky Way?

Jun 19

Revenues Working Against Apyx Medical Corporation's (NASDAQ:APYX) Share Price Following 25% Dive

Apr 18

Apyx Medical Corporation (NASDAQ:APYX) Analysts Just Slashed This Year's Estimates

Mar 26

Take Care Before Diving Into The Deep End On Apyx Medical Corporation (NASDAQ:APYX)

Feb 16

Is Apyx Medical (NASDAQ:APYX) A Risky Investment?

Sep 14

Does Apyx Medical (NASDAQ:APYX) Have A Healthy Balance Sheet?

Jun 07

Forecast: Analysts Think Apyx Medical Corporation's (NASDAQ:APYX) Business Prospects Have Improved Drastically

Mar 21

Here's Why We're Watching Apyx Medical's (NASDAQ:APYX) Cash Burn Situation

Dec 14

We're Not Very Worried About Apyx Medical's (NASDAQ:APYX) Cash Burn Rate

Aug 30

Apyx Medical GAAP EPS of -$0.16 beats by $0.03, revenue of $10.3M misses by $0.26M

Aug 11

Apyx Medical gets FDA nod for Renuvion's use in improving loose skin on neck, chin

Jul 18

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:APYX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	61	-18	-6	N/A	2
12/31/2025	54	-24	-23	N/A	4
12/31/2024	51	-25	-22	N/A	4
6/30/2024	49	-28	-10	-9	N/A
3/31/2024	50	-23	-10	-10	N/A
12/31/2023	52	-19	-6	-5	N/A
9/30/2023	50	-15	-8	-8	N/A
6/30/2023	47	-16	-17	-17	N/A
3/31/2023	44	-21	-18	-18	N/A
12/31/2022	45	-23	-21	-20	N/A
9/30/2022	49	-19	-17	-16	N/A
6/30/2022	51	-18	-15	-14	N/A
3/31/2022	52	-16	-14	-13	N/A
12/31/2021	49	-15	-11	-10	N/A
9/30/2021	43	-15	-12	-12	N/A
6/30/2021	38	-14	-11	-11	N/A
3/31/2021	31	-15	-11	-11	N/A
12/31/2020	28	-12	-17	-16	N/A
9/30/2020	25	-16	-19	-18	N/A
6/30/2020	25	-16	-21	-20	N/A
3/31/2020	28	-16	-22	-21	N/A
12/31/2019	28	-20	-20	-18	N/A
9/30/2019	26	-18	-35	-33	N/A
6/30/2019	22	-15	-30	-30	N/A
3/31/2019	19	-14	-25	-25	N/A
12/31/2018	17	-11	-21	-21	N/A
9/30/2018	14	-10	-2	-2	N/A
6/30/2018	13	-12	-2	-1	N/A
3/31/2018	5	-15	N/A	-2	N/A
12/31/2017	10	-14	N/A	-4	N/A
9/30/2017	-12	-19	N/A	-5	N/A
6/30/2017	-4	-17	N/A	-4	N/A
3/31/2017	37	-4	N/A	-3	N/A
12/31/2016	9	-12	N/A	-3	N/A
9/30/2016	35	-5	N/A	-3	N/A
6/30/2016	33	-5	N/A	-4	N/A
3/31/2016	31	-6	N/A	-6	N/A
12/31/2015	30	8	N/A	-6	N/A
9/30/2015	29	4	N/A	-5	N/A
6/30/2015	28	3	N/A	-3	N/A
3/31/2015	27	4	N/A	-1	N/A
12/31/2014	28	-18	N/A	0	N/A
9/30/2014	26	-18	N/A	-2	N/A
6/30/2014	25	-15	N/A	-3	N/A
3/31/2014	24	-16	N/A	-3	N/A
12/31/2013	24	-7	N/A	-3	N/A
9/30/2013	24	-2	N/A	-1	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: APYX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: APYX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: APYX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: APYXDie Einnahmen des Unternehmens (12.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: APYXDie Einnahmen des Unternehmens (12.5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von APYX in 3 Jahren voraussichtlich hoch sein wird

Apyx Medical Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus estimates of losses per share improve by 12%

Apyx Medical Corporation Revises Earnings Guidance for the Full Year Ended December 31, 2024

Apyx Medical Corporation Reaffirms Earnings Guidance for the Full Year Ending December 31, 2024

Consensus revenue estimates fall by 17%

Apyx Medical Corporation Provides Earnings Guidance for the Year Ending December 31, 2024

Apyx Medical Corporation Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023

Recent updates

New minor risk - Share price stability

Is There An Opportunity With Apyx Medical Corporation's (NASDAQ:APYX) 41% Undervaluation?

Consensus estimates of losses per share improve by 12%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Apyx Medical Corporation Revises Earnings Guidance for the Full Year Ended December 31, 2024

Apyx Medical Corporation (NASDAQ:APYX) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny

We Discuss Why Apyx Medical Corporation's (NASDAQ:APYX) CEO Compensation May Be Closely Reviewed

Apyx Medical Corporation to Report Q2, 2024 Results on Aug 08, 2024

Now 21% undervalued after recent price drop

Now 22% undervalued after recent price drop

Now 21% undervalued after recent price drop

Apyx Medical Corporation, Annual General Meeting, Aug 08, 2024

Apyx Medical Corporation, Annual General Meeting, Aug 08, 2024

Is Apyx Medical (NASDAQ:APYX) Using Debt In A Risky Way?

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Apyx Medical Corporation Reaffirms Earnings Guidance for the Full Year Ending December 31, 2024

New major risk - Revenue and earnings growth

Apyx Medical Corporation to Report Q1, 2024 Results on May 09, 2024

Revenues Working Against Apyx Medical Corporation's (NASDAQ:APYX) Share Price Following 25% Dive

Consensus revenue estimates fall by 17%

Apyx Medical Corporation (NASDAQ:APYX) Analysts Just Slashed This Year's Estimates

Apyx Medical Corporation Provides Earnings Guidance for the Year Ending December 31, 2024

Full year 2023 earnings: EPS misses analyst expectations

Apyx Medical Corporation to Report Q4, 2023 Results on Mar 21, 2024

Take Care Before Diving Into The Deep End On Apyx Medical Corporation (NASDAQ:APYX)

Apyx Medical Corporation Announces Peer-Reviewed Clinical Publication Evaluating the Safety of Renuvion® Following Liposuction in Multiple Areas of the Body

New major risk - Revenue and earnings growth

Apyx Medical Corporation Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023

Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer, Effective December 4, 2023

Apyx Medical Corporation Announces Resignation of Tara Semb as Chief Financial Officer

Apyx Medical Corporation Announces Resignation of Tara Semb as Chief Financial Officer

New major risk - Share price stability

President recently bought US$79k worth of stock

Consensus revenue estimates fall by 11%

Apyx Medical Corporation announced that it expects to receive $45 million in funding

Price target increased by 16% to US$9.00

New minor risk - Market cap size

Apyx Medical Corporation to Report Q3, 2023 Results on Nov 09, 2023

Is Apyx Medical (NASDAQ:APYX) A Risky Investment?

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Apyx Medical Corporation Reaffirms Financial Guidance for the Year Ending December 31, 2023

New major risk - Share price stability

Executive Vice President exercised options and sold US$87k worth of stock

Apyx Medical Corporation to Report Q2, 2023 Results on Aug 10, 2023

Executive Vice President notifies of intention to sell stock

Apyx Medical Corporation, Annual General Meeting, Aug 10, 2023

Apyx Medical Corporation Announces FDA 510(k) Clearance for the Renuvion® Micro Handpiece

Does Apyx Medical (NASDAQ:APYX) Have A Healthy Balance Sheet?

Consensus estimates of losses per share improve by 15%

Price target increased by 33% to US$8.00

Apyx Medical Corporation Updates Earnings Guidance for the Year Ending December 31, 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 11%

Forecast: Analysts Think Apyx Medical Corporation's (NASDAQ:APYX) Business Prospects Have Improved Drastically

Full year 2022 earnings: EPS misses analyst expectations

Apyx Medical Corporation to Report Q4, 2022 Results on Mar 16, 2023

Apyx Medical Corporation Announces FDA 510(K) Submission for the Use of the Renuvion® Apr. Handpiece for the Coagulation of Subcutaneous Soft Tissues Where Needed, Following Liposuction

Apyx Medical Corporation Launches New 'Apyx One Console' for Cosmetic Surgical Procedures in the United States

Apyx Medical Corporation Provides Revenue Guidance for the Fourth Quarter and Full Year 2022

Here's Why We're Watching Apyx Medical's (NASDAQ:APYX) Cash Burn Situation

Consensus revenue estimates fall by 15%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Price target decreased to US$10.33

Apyx Medical Corporation Updates Earnings Guidance for the Year Ending December 31, 2022

Apyx Medical Corporation to Report Q3, 2022 Results on Nov 10, 2022

Insufficient new directors

President recently bought US$70k worth of stock